The CDK2-proteasome-XPO1 cluster was enriched with pharmacological options, including the proteasome inhibitor bortezomib, which is available clinically, and CDK2 and XPO1 inhibitors, which are under active clinical trials for various tumor types (Figure 2(c)) [29, 30]: XPO1 inhibitors have been used to target platinum-resistant ovarian tumors [31] and have been described as potentially inhibiting abnormal NF-kB signaling [32]. Here, NFKB1 is linked to neoplasm.